Physician profile
Marcelo E Nasif
NPI 1912936907
$1,410.86
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $458 · 2021: $58.72 · 2022: $45.18 · 2023: $92.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $389.38 | 2019-2020 | |
| Viiv Healthcare Company | $292.28 | 2019-2023 | Apretude, Dovato |
| Merck Sharp & Dohme LLC | $227.12 | 2019-2023 | Pifeltro, Dificid, Delstrigo |
| Janssen Biotech, INC. | $155.31 | 2019-2022 | |
| Insmed, INC. | $93.69 | 2020-2022 | |
| Abbvie INC. | $42.48 | 2021 | |
| Aimmune Therapeutics, INC. | $37.50 | 2023 | |
| Astellas Pharma US INC | $37.19 | 2019 | |
| Theratechnologies INC. | $34.30 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $32.08 | 2019 | |
| Allergan, INC. | $25.46 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.00 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.28 | 2019 | |
| Melinta Therapeutics, LLC | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcelo Nasif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.